AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00405405 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
Study NCT00393523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified Process Hepatitis B Vaccine
Description: Single dose 5 µg/0.5ml modified process hepatitis B vaccine
Study NCT00393523 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Modified Process Hepatitis B Vaccine
Description: Single dose 5 µg/0.5ml modified process hepatitis B vaccine
Study NCT00393523 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Comparator: ENGERIX-B
Description: Single dose 10 µg/0.5ml ENGERIX-B
Study NCT02650232 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SOMNOtouch device (Somnomedics)
Description: In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
Study NCT02650232 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthostatic test
Description: For each arm we will proceed to an orthostatic test day one and day two with :~* 10 minutes in supine position~* 10 minutes in sitting position~* 5 minutes in standing position~* 5 minutes in supine position
Study NCT02650232 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Finapres Nova device (FMS system)
Study NCT00227864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Study NCT00227864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Study NCT03282279 — intervention group
Intervention type: PROCEDURE
Intervention: TVOR
Description: Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
Study NCT03973866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implantation of alfapump
Study NCT01992705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable
Description: Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
Study NCT01992705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: -Oxaliplatin 85 mg/m2 IV on Day 1
Description: Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
Study NCT01992705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: -Irinotecan 180 mg/m2 IV on Day 1
Description: Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
Study NCT01992705 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
Description: 5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
Study NCT00640796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical donor derived natural killer cell infusion
Description: Therapeutic cell infusion
Study NCT00640796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
Study NCT00640796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Cell selection system based on magnetic-activated cell sorting
Study NCT00744263 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VACCINE: placebo
Description: 0.5 mL, single intra-muscular injection
Study NCT00744263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VACCINE: 13-valent pneumococcal conjugate vaccine
Description: 0.5 mL, single intra-muscular injection
Study NCT02557490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and raltitrexed
Description: TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)
Study NCT02873819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GL-0817
Description: GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
Study NCT02873819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiltonol
Description: Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
Study NCT02873819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
Study NCT02873819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
Study NCT02873819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
Study NCT00875732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi Ventricular Pacing
Study NCT00875732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right Ventricular Pacing
Study NCT00288028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Dose of Bortezomib\* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01433484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of Weight Loss--Control
Description: As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
Study NCT01433484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance of Weight Loss--Experimental
Study NCT01885260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx - Dose Level 1
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Study NCT01885260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx - Dose Level 2
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Study NCT01885260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Study NCT02995902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Study NCT02995902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT03911453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
Study NCT03968315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragm Fluoroscopy
Description: Undergo diaphragm fluoroscopy
Study NCT03968315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04000594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
Study NCT02204579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP795
Study NCT02541214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trial Nasal Mask
Study NCT02543190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compliance surveillance and improvement strategy
Description: External monitor to ensure compliance with an educational protocol.
Study NCT04301440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The emission of electromagnetic with the probes
Description: The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
Study NCT04301440 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The emission of electromagnetic without the probes
Description: The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
Study NCT01755624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A device
Study NCT01755624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care
Study NCT02911350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Suppressors
Study NCT02911350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02911350 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT03926793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002
Description: GB002 low dose or high dose for inhalation
Study NCT03926793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for inhalation
Study NCT03926793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 or Placebo delivery
Study NCT00856661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
Study NCT00856661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV, single bolus over 1 to 2 minutes on 1st day
Study NCT01800695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion
Study NCT01800695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered per label and local prescribing regulations.
Study NCT01800695 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation
Description: Whole Brain radiation will be administered in 30 fractions.
Study NCT01704911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transradial Coronary Intervention
Study NCT01704911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfemoral Coronary Intervention
Study NCT01704911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stent System
Description: Any kind of coronary stent system
Study NCT01233583 — intervention group
Intervention type: DRUG
Intervention: Dovobet, neotigason, etanercept, adalimumab. infliximab
Description: Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
Study NCT00486135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
Study NCT00486135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
Study NCT01925027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano+ DES
Description: All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
Study NCT03556358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TX05 (trastuzumab)
Description: 8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
Study NCT03556358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: 8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
Study NCT03556358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
Study NCT03556358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
Study NCT03556358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
Study NCT03556358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
Study NCT03556358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
Study NCT03556358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
Study NCT02676908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression socks for 2 weeks
Description: Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
Study NCT00594971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Organisational intervention
Description: A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
Study NCT00594971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referral to a specialist palliative care team.
Description: Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
Study NCT01298921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
Study NCT01298921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: 100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
Study NCT02592200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri DSM 27123
Description: 109 CFU (divided in two doses) per day for 28 days
Study NCT02592200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses per day for 28 days
Study NCT00399763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
Study NCT00399763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
Study NCT02681705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
Study NCT02681705 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Radiation
Description: Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
Study NCT00780182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX001
Description: CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
Study NCT03515057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single lead handheld electrocardiogram
Description: Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
Study NCT03904511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Souroubea-Platanus Preparation
Description: Extracts of S. Sympetala and P. occidentalis.
Study NCT03904511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03908073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: The use of a transcutaneous vagal nerve stimulator by the participant
Study NCT03908073 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: The use of a transcutaneous vagal nerve stimulator by the participant
Study NCT02260505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib maintenance
Description: Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
Study NCT02638623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: 2L Lactated Ringer administered prior to primary knee or hip arthroplasty
Study NCT02638623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No additional fluids will be administered
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT05728567 — intervention group
Intervention type: OTHER
Intervention: whether the participants had T2DM
Description: whether the participants had T2DM
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 1 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
Study NCT03761134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
Study NCT00256854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.